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SUMOylation has emerged as an important regulatory mechanism for protein 
function. SUMO-specific proteases (SENPs) are essential for removing SUMO from 
conjugated proteins in many different systems, but the physiological functions of 
SENPs are poorly understood. STAT5 (Signal Transducer and Activator of 
Transcription 5) plays a critical role in the development of lymphoid cells. However, 
it is not known whether STAT5 is regulated by the SUMOylation pathway. Here, we 
showed that SUMOylated STAT5 is accumulated in SENP1-/- lymphoid precursors. 
SENP1 deficiency results in severe defects in early T and B cell development, 
similar to that observed in mice harboring a complete inactivation of STAT5. 
Because STAT5 is SUMOylated and acetylated at the same lysine residue, SENP1 
deficiency blocks STAT5 in the SUMOylation state, resulting in diminished STAT5 
acetylation and phosphorylation, and defective lymphoid development. Thus, our 
results reveal a novel function of SENP1 in the regulation of early lymphoid 
development via an acetylation/SUMOylation switch in STAT5.   
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INTRODUCTION 
 
SUMO (small ubiquitin-like modifier) 
 
In eukaryotes, protein function is tightly regulated by multiple mechanisms, 
such as control of transcription and translation, and post-translational modifications. 
Over the past decade, posttranslational modifications of proteins, including 
phosphorylation, methylation, acetylation and ubiquitination, have been extensively 
studied. SUMOylation, a posttranslational modification of proteins by SUMO, has 
emerged recently as an important regulatory mechanism in cell physiology.  
SUMO was discovered in the mid 1990s. The Saccharomyces cerevisiae 
SMT3 gene was first described as a suppressor of MIF2 protein required for mitotic 
spindle integrity in 1995 (1). In 1996, using the death domain in the cytoplasmic tail 
of Fas/APO-1 and TNF receptor 1 as bait in the yeast two-hybrid system, our 
laboratory reported the isolation of a novel death domain-interacting protein, Sentrin 
(later re-named as SUMO-1), which exhibited homology to ubiquitin, Nedd8 and 
SMT3. Interestingly, Overexpression of Sentrin protected cells from both anti- 
Fas/APO-1 and TNF-induced cell death. However, the mechanism by which Sentrin 
inhibits the cell death signaling remains to be elucidated (2). At the same time, five 
other groups identified different human and mouse homologs of S. cerevisiae SMT3, 
and called them different names, including PIC1 (PML interacting protein 1), GMP1 
(GAP-modifying protein 1), Ubl1 (ubiquitin-like protein 1), SUMO-1 (small-
ubiquitin-related modifier) (3-6), and human HSMT3 (later called human SUMO-2) 
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(7).  Although human SUMO-1 has only a low sequence similarity of 18% to 
ubiquitin, NMR structure analysis revealed that SUMO-1 and Ubiquitin display 
similar 3-D structure (8).  The C-terminal diglycine residues of both SUMO and 
ubiquitin are required for formation of an isopeptide bond with the -NH2 group of 
lysine residue in targeted proteins. 
 Four SUMO homologs have been indentified in mammalian cells. SUMO-1 
shares 47% similarity at the protein level with SUMO-2 and 3, whereas SUMO-2 
and 3 are 95% identical. In contrast to SUMO-1, SUMO-2 and SUMO-3 have a 
consensus SUMOylation site at their N-terminal region and can form poly-SUMO 
Chains (9). SUMO-1, 2 and 3 are ubiquitously expressed in all tissues, while SUMO-
4 expression is limited to immune tissues and kidney (10, 11). The conjugation of 
SUMO-4 to substrates in vivo still remains obscure.  
 
The SUMOylation pathway 
 
All SUMO proteins are synthesized as immature forms that must be 
processed to expose the C-terminal di-glycine motif to generate the mature forms. 
This processing is carried out by the sentrin/SUMO-specific protease (SENP) family. 
The mature form of SUMOs is activated by a SUMO-activating enzyme (E1), a 
heterodimer containing SAE1 (SUMO-activating enzyme subunit 1) and SAE2, 
transferred by a SUMO-conjugating enzyme (E2) UBC9, and in some cases, to a 
SUMO protein ligase (E3) that catalyzes the formation of an isopeptide bond 
between the C-terminal carboxy group of SUMO and the ε-amino group of lysine in 
 2
protein substrates. Lysine residues subject to SUMO modification are usually found 
within a SUMO modification consensus motif, ψKXE/D (where ψ is a large 
hydrophobic residue and X is any residue). Currently, several SUMO E3 ligases 
have been characterized, including PIAS (protein inhibitor of activated STAT) 
proteins, the nucleoporin RanBP2 and the polycomb protein Pc2 (12, 13).  
The covalent modification of proteins by SUMO can be reversed by SENPs, 
as illustrated in Figure 1. Thus, SENP regulates SUMOylation via (1) its C-terminal 
hydrolase activity required for removing C-terminal amino acids from SUMO to 
reveal the diglycine residues important for conjugation to SUMO substrates and/or 
(2) its isopeptidase activity that is essential for removing SUMO from conjugated 
substrates. Two yeast SENPs, including Ulp1 and Ulp2/Smt4 were characterized first 
(14, 15). Ulp1 has both the C-terminal hydrolase activity and the isopeptidase 
activity, while Ulp2 possesses only the isopeptidase activity.  
In 2000, our laboratory cloned the first mammalian Sentrin/SUMO-specific 
protease (SENP1), which is distantly related to the yeast Ulp1 (16). Currently, six 
SENPs have been identified in mammalian cells. They can be divided into three 
subfamilies on the basis of their sequence homology, cellular localization and 
substrate specificity (17-19). The first subfamily, consisting of SENP1 and SENP2, 
can process either SUMO-1 or SUMO-2/3-conjugated proteins. The second 
subfamily contains SENP3 and SENP5, which prefer SUMO2/3 as substrates and are 
localized in the nucleolus. The third subfamily including SENP6 and SENP7 also 
favors SUMO2/3-modified substrates.     
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Figure 1. SUMOylation vs deSUMOylation. Target protein can be SUMOylated 
by SUMO E1, E2 and E3 ligases, and SUMO-conjugated protein can be 
deSUMOylated by Sentrin/SUMO-specific proteases (SENPs) to remove SUMO 
from target. 
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Biological Function of SUMO-specific proteases  
 
SUMOylation has been shown to play key roles in regulating diverse cellular 
processes, including transcription, DNA repair, cell-cycle progression and signal 
transduction from yeast to human (13, 19). SENPs are essential for reversing 
SUMOylation in many different systems; however, the physiological significance 
and in vivo functions of SENPs are poorly understood. 
 In an attempt to understand the role of SENP1 in development, Yamaguchi 
et al. generated mice from an ES cell line with a retroviral vector that was randomly 
inserted into the enhancer region on the SENP1 gene (20). This random insertion 
reduced expression of the SENP1 transcript, resulting in embryonic lethality between 
E12.5 and E14.5. Interestingly, the mutation caused the accumulation of the 
SUMOylated forms of a number of proteins both in the fetus and placenta. These 
data suggest that SENP1 is important for regulating the levels of SUMOylated 
proteins during embryonic development. However, the exact molecular mechanism 
by which SENP1 contributes to development is not clear. 
Because SENP1 expression in Yamaguchi’s mouse model is partially 
blocked, our laboratory generated complete SENP1 knockout mice to further 
evaluate the contribution of SENP1 in development. SENP1 knockout (KO) mice 
were generated from an embryonic stem cell line with a gene trap vector that was 
inserted into the mouse SENP1 open reading frame at codon 310 (21). This insertion 
completely blocked SENP1 expression. SENP1 deficiency caused embryonic 
lethality between E13 and E15, due to severe fetal anemia (21). SENP1 controls EPO 
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production by regulating the stability of hypoxia-inducible factor 1 (HIF1). In the 
absence of SENP1, hypoxia induced HIF1 SUMOylation, thereby leading to 
HIF1 ubiquitylation and proteasomal degradation. 
Recently, another group created SENP1 KO mice based on a Cre–loxP 
system (22). SENP1lox/lox mice were crossed with β-actin–Cre mice to mediate a 
recombination in vivo, resulting in a complete deletion of SENP1 exon 5 and exon 6 
and a frameshift of the downstream catalytic domain. This global deletion of SENP1 
leads to embryonic lethality between embryonic day 13.5 and postnatal day 1, and 
anemia (22). SENP1 controls GATA1 activation and erythropoiesis through 
deSUMOylation of GATA1.   
Two groups have independently uncovered the role of SENP2 and the 
importance of SUMOylation in development. Chiu and colleagues generated SENP2 
KO mice using the Cre-LoxP system and demonstrated that SENP2-/- mice exhibited 
embryonic lethality between E10.5 to E11.5, due to a placenta defect (23). In the 
absence of SENP2, SUMOylated Mdm2 accumulates in the nucleus, where it is 
unable to promote p53 degradation. Accumulation of p53 in trophoblast progenitors 
causes cell growth arrest and subsequent defect in placental development. Our 
laboratory generated SENP2 KO mice using a gene trap vector inserted into intron 
10 of SENP2 genomic DNA and disrupted the transcript of the catalytic domain of 
SENP2 (24). Deletion of the murine SENP2 gene causes embryonic lethality at E10, 
due to a profound defect in the cardiac development (24). The expression of Gata4 
and Gata6 genes is essential for cardiac development, and is regulated by occupancy 
of Pc2/CBX4, a polycomb repressive complex 1 (PRC1) subunit, on their promoters. 
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In the absence of SENP2, SUMOylated Pc2/CBX4 accumulates and Pc2/CBX4 
occupancy at the promoters of PcG target genes is markedly increased, leading to 
repression of Gata4 and Gata6 transcription (24). The phenotypic differences 
observed in these two SENP2 KO mouse models are difficult to explain. It is 
possible that the KO strategies used to inactivate the SENP2 gene may also 
contribute to the difference in phenotypes observed. Future studies using tissue 
specific gene-targeting (Cre/loxP system) to inactivate the SENP2 gene are needed to 
further characterize the role of SENP2 and its target genes in development. 
A more recent study by Dou et al. has revealed that SENP6 regulates the 
SUMOylation status of RPA70, which plays a critical role in DNA repair through 
homologous recombination (HR) (25). SENP6-depleted cells exhibited the typical 
phenotypes of DNA damage response, including the accumulation of γ-H2AX foci, 
activated cell cycle check points (phosphorylated Chk1 and Chk2) and defective cell 
cycle progression in both S phase and G2/M phases, correlating with the 
accumulation of SUMOylated RPA70. Biochemical experiments further indicated 
that RPA70 SUMOylation serves as HR mediator to facilitate recruitment of Rad51 
to the DNA damage foci to initiate DNA repair through HR. This study clearly 
demonstrates the role of SENP6 in regulating RPA70 SUMOylation and HR. 
However, suppression of SENP6 accumulated DNA damage foci, suggesting that 
SENP6 is also essential for maintaining genomic stability, possibly through 
regulation of DNA replication or telomere elongation/maintenance. Further 
investigations are required to clarify this important issue. 
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Molecular mechanisms by which SUMOylation regulates transcription  
 
SUMOylation plays a critical role in regulating gene expression by various 
mechanisms. Instead of single-site action, many proteins are dynamically modified at 
multiple sites by different modifications, including phosphorylation, acetylation, 
ubiquitination, and sumoylation. This phenomenon is known as multisite 
modification (26). Hietakangas and others identified a PDSM (phosphorylation-
dependent sumoylation motif), containing a SUMO consensus site and an adjacent 
proline-directed phosphorylation site (ΨKxExxSP) (27, 28). This highly conserved 
motif regulates phosphorylation-dependent sumoylation of multiple substrates, such 
as heat-shock factors (HSFs), GATA-1, and myocyte enhancer factor 2 (MEF2). 
Thus, SUMOylation can affect other modifications or function of proteins.  
 Since a lysine residue can be a target of different posttranslational 
modifications, SUMOylation can block alternative lysine-targeted modifications 
such as ubiquitination, methylation or acetylation. Ubiquitination and proteasome-
mediated degradation of IκBα are known to be crucial for activation of NF-κB. In 
1998, Hay’s group demonstrated that IκBα is SUMOylated on K21, which is also 
targeted by ubiquitination (29). SUMOylated IκBα cannot be ubiquitinated and is 
therefore resistant to proteasome-mediated degradation. Thus, by blocking 
ubiquitination, SUMOylation creates a privileged pool of IκBα that is resistant to 
signal-induced degradation (29). Transcriptional activity of transcription factors, 
sush as SP3 and MEF2A, can be regulated by interplay between SUMOylation and 
 8
acetylation on the same lysine residue (30, 31). Interestingly, an acetylation-
sumoylation switch on MEF2 is further regulated by its phosphorylation (31). 
Many transcription factors, coactivators, or corepressors are SUMOylated, 
resulting in alterations of their cellular localization, stability, and interaction with 
binding partners. In most cases, SUMOylated proteins suppress transcription, 
possibly due to their interaction with co-repressors. Therefore, blocking SUMO 
conjugation to substrates by lysine-to-arginine mutation of SUMOylation sites or by 
overexpression of SENPs can increase the transcriptional activity of transcription 
factors (32).   
An increasing number of studies support the notion that SUMOylation of 
proteins alters their interaction with binding partners, in particular those having a 
SUMO-interaction motif (SIM) (33, 34). The SIM mediates non-covalent 
interactions between SIM-containing proteins and SUMO. This motif consists of the 
short hydrophobic peptide sequence V/I/L-V/I/L-X-V/I/L or V/I/L-X-V/I/L-V/I/L 
and in some cases, are preceded, or followed, by a stretch of acidic amino acids. A 
recent study by Glass group has highlighted the importance of SIM in regulation of 
Toll-like receptors (TLRs) in macrophages (35). Transcriptional activation of many 
TLR-responsive genes is archived by an initial de-repression step that nuclear 
receptor co-repressor (NCoR) complexes are actively removed from the promoters of 
target genes. Ligand-dependent SUMOylation of liver X receptors (LXRs) inhibits 
TLR4-induced transcription potently by preventing the NCoR clearance step. The 
study has demonstrated that SUMOylated LXRs block NCoR turnover by binding to 
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a conserved SUMO2/SUMO3-interaction motif in CORO2A, a component of the 
NCoR complex, and preventing nuclear actin recruitment.  
Another example of SIM is SUMO-targeted ubiquitin Ligase (STUbL) family 
of proteins, which selectively ubiquitinates sumoylated proteins and proteins 
containing SUMO-like domains (SLDs). STUbL recruitment to sumoylated/SLD 
proteins is mediated by tandem SUMO interaction motifs (SIMs) within the STUbLs 
N-terminus (36, 37). Although the roles of STUbLs in regulating transcription and 
DNA repair in yeast have been documented, little is known about their functions in 
mammalian cells.  
 
STAT proteins 
 
It is well known that cytokines play a central role in the regulation of the 
immune system. Three key families of transcription factors that are widely used 
downstream of cytokine-mediated to control gene expression include the signal 
transducer and activator of transcription (STAT) family of proteins, nuclear factor-
kB (NF-kB) and SMA (small body size)-and MAD (mothers against 
decapentaplegic)-related proteins (SMADs) (38). In 1992, STAT1 and STAT2 were 
the first members of STAT proteins identified as mediators of the cellular response 
to interferons (IFNs) (39, 40). Currently, seven mammalian STATs have been 
identified, including STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and 
STAT6, encoded by different genes (41). In the human genome, Stat1 and Stat4 
genes are clustered together on chromosome 2, and Stat3, Stat5a and Stat5b genes 
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are clustered together on chromosome 17, whereas Stat2 and Stat6 genes are 
clustered together on chromosome 12 (42). All STAT proteins share six structural 
regions: an N-terminal domain (ND), a coil-coil domain (CC), a DNA-binding 
domain (DBD), a linker domain (L), a Src homology 2 (SH2) domain, and a 
transcriptional activation domain (TAD) at the carboxy (C) terminus. A single 
tyrosine residue (Y700) located in the TAD is required for STAT activation. 
The JAK (Janus kinase)-STAT signaling pathway consists of three main 
components: a receptor, JAK and STAT. Tyrosine kinases of the JAK family, 
including tyrosine kinase 2 (TYK2), JAK1, JAK2 and JAK3, are physically 
associated with the intracellular domains of many cytokine receptors. After cytokines 
bind to their cognate receptor on the cell surface, JAKs are activated and they then 
phosphorylate the cytoplasmic tails of the cytokine receptors at tyrosine residues, 
leading to recruitment and phosphorylation of STATs. Subsequently, activated 
STATs in the cytoplasm translocate to the nucleus, where they bind to specific DNA 
sites and activate the transcription of their specific genes.  
 
Regulation of STATs by acetylation 
 
In eukaryotic cells, chromatin is composed of DNA, histones and other 
nuclear proteins, and can be broadly classified into condensed heterochromatin and 
decondensed euchromatin. DNA in heterochromatin is inaccessible to enzymes for 
processes such as transcription, recombination and DNA repair while euchromatic 
DNA is accessible and active for these processes. Constitutive heterochromatin is 
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formed at repetitive DNA sequences, such as pericentromeres and telomeres, 
whereas the formation of facultative heterochromatin is inducible, and is often 
associated with a change in cell phenotype.   
A variety of modifications at the N-terminal tail of histones, such as 
acetylation, methylation and phosphorylation form the basis of the “histone code”, 
which can act as either repressive or active marks (43). These histone modifications 
recruit distinct protein complexes that affect chromatin structure. For histone lysine 
methylation (mono-, di-, and tri-methylation), H3 methylated at lysine-4 (K4), K36, 
and K79 are enriched in active chromatin, whereas methylation of H3-K9, H3-K27, 
and H4-K20 is responsible for heterochomatic silencing (44-46). Acetylation of 
histones H3 and H4 is associated with transcriptionally active chromatin. The role of 
histone lysine modifications in transcription regulation is well established; however 
modifications of non-histone proteins, in particular by acetylation, have recently 
emerged as an important mechanism of epigenetic regulation in transcription (47).  
The histone acetyltransferases CREB-binding protein (CBP)/p300 have been 
shown to interact with various STAT family members within both the C-terminal 
TAD and N-terminal domain, and promote STAT-mediated transcription (48-51). 
This raised the possibility that STATs could be modified by acetylation. Several 
studies have been reported concerning the acetylation of different STAT family 
members. STAT6 was the first STAT protein shown to be a target of acetylation 
(52). STAT1 is modified by acetylation at lysines 410 and 413. Interestingly, a 
phosphorylation-acetylation switch regulates STAT1 signaling (53, 54). Recent 
studies by Chin and colleagues reveal that STAT3 is acetylated at lysine 685 by 
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p300/CBP and that this modification is essential for STAT3 to form stable dimers 
and to activate transcription (55), whereas STAT2 acetylation on Lys390 regulates 
STAT2:STAT1 interaction (56), and STAT5 acetylation is required for dimerization 
(57). These studies clearly indicate that modification of STATs by acetylation is 
critical for regulating the JAK-STAT signaling pathway. 
 
 
Regulation of STATs by PIAS (Protein Inhibitor of Activated STAT)  
 
The mammalian protein inhibitor of activated STAT (PIAS) family of 
proteins was initially identified as negative regulators of STAT signaling (58, 59). 
The PIAS family includes PIAS1, PIAS3, PIASx (also known as PIAS2) and PIASy 
(also known as PIAS4). Except for PIAS1, each PIAS protein has two isoforms. 
Biochemical studies have revealed that more than 60 proteins, most of them 
transcription factors, can be regulated by members of the PIAS family through 
multiple mechanisms (38). First, a PIAS protein might block the DNA-binding 
activity of a transcription factor. A study by Shuai’s group showed that Pias1 
Deletion enhanced the antiviral activity of IFN-- or IFN-. As a result, Pias1-/- 
mice showed increased protection against pathogenic infection. This is probably 
because PIAS1 selectively regulates a subset of IFN-- or IFN--inducible genes by 
interfering with the recruitment of STAT1 to the gene promoter (60). Secondly, a 
PIAS protein might recruit other co-regulators, such as histone deacetylases 
(HDACs), to repress transcription. For example, Shuai’s group has recently reported 
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that PIAS1 binding to the Foxp3 promoter leads to recruitment of DNA 
methyltransferases and heterochromatin protein 1 for epigenetic modifications (61). 
Pias1 deletion resulted in promoter demethylation, reduced histone H3 methylation 
at Lys9, and enhanced promoter accessibility. As a result, Pias1-/- mice showed an 
increased natural CD4(+)Foxp3(+) regulatory T (T(reg)) cell population and were 
resistant to the development of experimental autoimmune encephalomyelitis (61). 
Thirdly, a PIAS protein might repress transcription by promoting the sumoylation of 
a transcription factor. Lastly, PIAS proteins might repress transcription by altering 
the localization of transcription factors. Despite their inhibitory roles in 
transcriptional regulation, PIAS proteins can regulate positively several transcription 
factors. For example, PIAS3 activates, whereas PIASy represses, the transcriptional 
activity of SMAD3 (62). 
 
Regulation of STATs by SUMOylation 
 
 PIAS proteins have been shown to function as SUMO-specific E3 ligases 
(63). This raises the possibility that STATs might be regulated by the SUMOylation 
pathway. Several groups have reported that STAT1 is SUMOylated on Lys703 in an 
overexpression system and that its SUMOylation can be greatly enhanced by PIAS 
proteins (63, 64). However, the in vivo function of SUMOylation in the regulation of 
STAT1 activity remains unknown. In addition, it is not known whether other STAT 
proteins can be modified by SUMO. 
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Biological function of STATs  
 
To elucidate the in vivo function of STAT proteins, all STAT genes have 
been gene-targeted in mice. The phenotypes of these mice reveal distinctive 
functions of STAT genes and the importance of these genes in regulating the 
development and function of the immune system (65-68).  
 
STAT1 
 
IFNs are known to regulate cellular antiviral, antiproliferative and 
immunological responses. IFNs include two types of IFNs, Type-I (IFN-α and IFN-
β) and Type-II (IFN-γ), which bind to bind to the Type-I IFN receptor and the Type-
II IFN receptor, respectively. IFN-α/β activates both STAT1 and STAT2, whereas 
IFN-γ stimulates the tyrosine phosphorylation of STAT1 but not STAT2. STAT1−/− 
mice are viable and fertile, but highly susceptible to microbial and viral infections 
and tumor formation due to severely impaired IFN responses (69, 70). In addition to 
IFNs, Stat1 can be activated by many growth factors including IL-6, IL-10, growth 
hormone and thrombopoietin. However, no major developmental defects were 
observed in STAT1−/− mice involving to non-IFN signaling. Thus, STAT1 is 
essential for the IFN-dependent signaling pathways.  
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STAT2 
 
 As discussed above, the major function of STAT2 is involved in IFN-α/β 
signaling. STAT2 knockout mice are fertile and viable but exhibit a number of 
defects in immune response, including an increased susceptibility to viral infection 
and the loss of IFN-α/β responsiveness (71).   
 
STAT3 
 
STAT3 can be activated by IL-6 family members, IFNγ, IL-10, and 
granulocyte-colony stimulating factor (G-CSF). Targeted deletion of STAT3 causes 
embryonic lethality at E7.5, suggesting that STAT3 plays a role during early 
embryogenesis (72). Increasing evidence suggests that STAT3 plays critical roles in 
the immune system, including inhibition of macrophage inflammatory signaling, 
control of dendritic cell differentiation, regulation of steady state and emergency 
granulopoiesis and regulation of B cell development (73-76). For example, Akira’s 
group generated STAT3 conditional KO mice by breeding of mice carrying a loxP-
flanked Stat3 allele with LysMcre mice in which the Cre-recombinase is expressed 
under control of the murine lysozyme M gene regulatory region (73). In these nice, 
STAT3 is deficient specifically in macrophages and neutrophils. The mutant mice 
exhibit increased production of inflammatory cytokines such as TNF-α, IL-1, and 
IFN-γ and impaired suppressive effects of IL-10 on inflammatory cytokine 
production from macrophages and neutrophils (73).    
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It was initially thought that after activation by professional antigen-presenting 
cells (APCs), naive CD4+ T cells were able to differentiate into effector cells, which 
could be divided into two subsets, T helper 1 (Th1) and T helper 2 (Th2) cells based 
on their cytokine-expression profiles and immune-regulatory function (77). Recently, 
three other subsets have been identified. The first new subset of TH cells is CD4+ 
CD25+ regulatory T cells (T reg cells), which play a central role in the maintenance 
of immune tolerance (78-80). Dong and colleagues have characterized two other 
novel TH-cell subsets, including follicular helper T cells and IL-17-producing CD4+ 
T (TH17) cells (also identified by Weaver’s group), which have crucial roles in 
immune regulation (81, 82). Interestingly, STAT3 is crucial for the differentiation of 
the TH17 cells (83). In contrast, activation of STAT5 is a critical factor in the 
induction and maintenance of FOXP3 expression in Treg cells (84). 
 
STAT4 
 
IL-12 promotes naïve CD4+ T cells (Th0 cells) to differentiate into Th1 cells, 
which secrete IL-2 and IFN-γ, and play a critical role in cellular-mediated immunity. 
STAT4 is activated by IL-12. STAT4-/- mice are viable and fertile. However, these 
mice showed impaired Th1 differentiation, IFN-γ production and cell-mediated 
immunity (85, 86), similar to the phenotypes of mice lacking IL-12 or IL-12R 
subunits.  
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STAT6 
 
STAT6 is activated in response to by IL-4 and IL-13. In addition, STAT6 is 
essential for differentiation of Th2 cells important for humoral immunity. 
Accordingly, STAT6-/- mice showed defects in IL-4-mediated functions including 
Th2 helper T-cell differentiation, expression of cell surface markers, and 
immunoglobulin class switching to IgE (87, 88).  
 
STAT5 
 
STAT5 was first isolated as a prolactin-induced transcription factor named 
mammary gland factor (MGF) in mammary gland tissue (89). STAT5 consists of two 
highly related genes encoding STAT5A and STAT5B proteins, which are 96% 
similar at the amino acid level (90). Activated by a number of cytokines, growth 
factors, and hormones, including IL-2, IL-3, IL-5, IL-7, IL-9, IL-15, GM-CSF, 
thrombopoietin, erythropoietin, and growth hormone, STAT5 has been implicated in 
various cellular processes, such as hematopoiesis, immunoregulation, reproduction, 
and lipid metabolism. Among all the STAT family members, only STAT5 has been 
demonstrated to play an essential role in regulating both T and B cell development 
(90).  
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Lymphoid development  
 
All hematopoietic cells are derived from hematopoietic stem cells (HSCs). 
According to a classical model, HSCs differentiate into common lymphoid 
progenitors (CLPs), which give rise to both B and T cells (91), as shown in Figure 2. 
Recent studies have suggested that HSCs differentiate into either common 
myeloid progenitors (CMPs) or lymphoid-primed multipotent progenitors (LMPPs) 
in the bone marrow (BM) (92). Myeloid cells stem from either CMPs or LMPPs, 
while erythroid cells and megakaryocytes develop from CMPs (93). Lymphocytes 
arise from LMPPs, which differentiate into the earliest lymphocyte progenitors 
(ELPs) (94). Subsequently, ELPs differentiate into common lymphoid progenitors 
(CLPs) and early thymic progenitors (ETPs) from which B and T cell development 
occurs in the BM and thymus, respectively. During embryonic development, 
hematopoietic stem cells arise in the aorta/gonad/mesonephros (AGM) region and 
migrate to the fetal liver where hematopoiesis takes places.   
As illustrated in Figure 3, thymocyte development proceeds through multiple 
stages, which can be characterized by the sequential expression of cell surface 
markers. The early immature T cells are CD4-CD8- double-negative (DN) 
thymocytes. They can be divided into four different developmental stages, defined 
based on their surface expression of CD44 and CD25 (95). Similarly, B cell 
development also occurs through various stages, including CLPs, pre-proB, early 
pro-B, late pro-B, pre-B, immature B and mature B cells. Each stage can be 
characterized by their expression of cell-surface markers, such as B220, CD43, 
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CD19, BP-1, HAS, IgM and IgD, and can be defined according to the Hardy 
nomenclature (Figure 4) (96).  
The development of T and B cells is tightly regulated by multiple 
transcription factors and cytokines (97, 98). IL-7 (Interleukin-7) is a non-redundant 
and essential cytokine for the development of both T and B cells (99). Its receptor 
consists of two chains, IL-7Rand common cytokine receptor -chain (C), which 
binds the Janus kinase 3 (Jak3) (100, 101). The C chain is expressed in various 
hematopoietic lineages, whereas the IL-7Rsubunit is preferentially expressed in 
the lymphoid system from CLPs to large pre-B and DN1-DN3 T cells as well as in 
thymic and peripheral CD4+ and CD8+ single-positive (SP) T cells (102).  
 Binding of IL-7 to its receptor triggers activation of Jak1 and Jak3, resulting 
in STAT5 activation, subsequent translocation to the nucleus and regulation of target 
gene transcription (Figure 5) (103). STAT5 contains two highly related isoforms, 
STAT5A and STAT5B, which are encoded by separate genes and play a critical role 
in the development and function of immune cells (90). 
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Figure 2. The lymphoid developmental pathway. Both B and T cells are 
differentiated from hematopoietic stem cells through multiple stages including 
common lymphoid progenitors, pro- and pre-B/T cells, before becoming mature B/T 
cells. 
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Figure 3. The T cell development pathway. T cell development proceeds through 
multiple stages, which can be characterized by the sequential expression of cell 
surface markers, including CD44, CD25, CD4 and CD8. The early immature T cells 
are CD4-CD8- double-negative (DN) thymocytes, which can be divided into four 
different developmental stages (DN1-4). 
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 Figure 4. The B cell development pathway. B cell development occurs through 
various stages, which can be characterized by their expression of cell-surface 
markers according to the Hardy nomenclature (Hardy and Hayakawa, 2001).  
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Figure 5. The IL-7R signaling pathway. In unstimulated state, STAT5 resides in 
the cytoplasm. Binding of ligand (IL7) to its receptor leads to phosphorylation of the 
cytoplasmic tail of receptor, resulting in recruitment of STAT5 to the receptor. 
STAT5 is phophorylated by JAK kinases. Phosphorylated STAT5 dimerizes and 
translocates to the nucleus, where it turns on the transcription of STAT5-specific B/T 
cells and then returns back to the cytoplasm. 
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AIM OF THE PRESENT STUDY 
 
SUMOylation has been shown to regulate a number of cellular processes, 
including transcription, DNA repair, cell-cycle progression and signal transduction 
from yeast to human (18, 19). Many transcription factors are SUMOylated, resulting 
in alteration of their function (32).  Previously, we reported that inactivation of the 
murine SENP1 gene results in embryonic lethality prior to embryonic day 16.5 
(E16.5), due to a severe defect in definitive erythropoiesis stemming from deficient 
Epo production (21). SENP1 KO mouse study revealed that SENP1 controls EPO 
production by regulating the stability of HIF1 (21). Despite extensive biochemical 
studies on SENPs in vitro, the physiological significance and in vivo functions of the 
SENPs remain poorly understood. In particular, the physiological function of SENP1 
in the development of lymphoid cells has not been defined. The overall aim of my 
PhD dissertation was to investigate the role of SENP1 in T and B lymphopoiesis 
using SENP1 KO mice that we described earlier (21).   
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RESULTS 
 
SENP1 is highly expressed at the early stages of T and B lymphocytes 
 
To investigate the role of SENP1 in lymphopoiesis, we first analyzed its 
expression pattern in lymphoid cells. Interestingly, SENP1 was highly expressed at 
the early stages of T and B cell development including DN2, DN3 and DN4 T cells 
and, pro-B and Pre-B cells, respectively (Figure 6), raising the possibility that 
SENP1 might participate in T and B lymphopoiesis. 
 
SENP1 deficiency impairs T cell development 
 
We next examined the phenotype of thymus in SENP1-/- embryos. 
Histological examination of thymic sections revealed that both the size and 
cellularity of E15.5 SENP1-/- thymi were markedly decreased compared with those 
of wild-type littermates (Figure 7). To check whether a partial or complete block in T 
cell development could explain thymic hypocellularity and smaller thymus size in 
SENP1-/- embryos, we cocultured hematopoietic stem cells (HSCs) isolated from 
fetal livers (FL) in E14.5 wild-type and SENP1-/- embryos with OP9 stromal cells 
expressing Delta-like 1 (OP9-DL1 cells) in the presence of cytokines Flt3L (FMS-
like tyrosine kinase 3 ligand) and IL-7 (Interleukin-7) to induce T cell differentiation 
in vitro (104). 
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Figure 6. SENP1 mRNA expression in hematopoietic lineage populations. Each 
population was isolated by flow-sorting from the thymus and bone marrow of 4- to 
6-week-old C57BL/6 mice. SENP1 mRNA expression was measured by quantitative 
RT-PCR using TaqMan assay kit from ABI. Gene expression was normalized to 18s 
rRNA level. The relative abundance is displayed as an average of triplicates of 
quantitative PCR in each sample, and error bars indicate ± SD. 
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Figure 7. SENP1 deficiency affects the thymic development. Hematoxylin and 
eosin staining of thymic sections (top panel, original magnification: 100x and bottom 
panel, original magnification: 400x) from wild-type (WT) and SENP1-/- (KO) 
embryos at E15.5. The results shown are a representative of at least four independent 
experiments. 
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After 7 days of co-culture, flow cytometric analysis revealed that most of the 
cells derived from both wild-type and SENP1-/- HSCs were immature CD4-CD8- 
(DN) thymocytes (Figure 8A, top panel). However, further segregation of DN 
thymocytes into distinct subsets (DN1-DN4) showed an increased frequency of DN1 
subset, and decreased frequencies of DN2 and DN3 subsets generated from SENP1-/- 
HSCs (Figure 8A, lower panel). Furthermore, the absolute numbers of DN2, DN3 
and DN4 T cells derived from SENP1-/- HSCs were significantly decreased 
compared with those of wild-type controls (Figure 8B). These results indicate that 
SENP1 is required for early T cell development at or before the DN2 stage.  
Under OP9-DL1 cell co-culture conditions, wild-type and SENP1-/- HSCs 
were unable to generate B and myeloid cells (Figures 9A and 9B). After 14 days of 
coculture on OP9-DL1 cells, despite a substantial decrease in the absolute cell 
numbers, CD4/CD8 double positive (DP), CD4 single positive (SP) and CD8 SP 
could still be generated from SENP1-/- HSCs (Figure 10). These results strongly 
suggest that SENP1 deficiency leads to an incomplete block in early T cell 
development.   
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Figure 8. SENP1 deficiency results in a severe defect in early T cell 
development. (A) FL-HSCs (Lin-c-Kit+Sca1+) from wild-type (WT) and SENP1-/- 
(KO) embryos at E14.5 were cocultured on OP9-DL1 stromal cells in the presence of 
IL-7 and Flt3L. After 7 days of coculture, cells were isolated and analyzed by flow 
cytometry for T cell markers CD4 and CD8 (top panel). Gated CD4-CD8- population 
was further analyzed based on CD44 and CD25 (lower panel). Data shown are 
representative of three independent experiments. (B) Absolute numbers of the 
indicated subpopulations of thymocytes were calculated based on flow cytometry 
(shown in B) and total thymocytes counts, and represented as mean ± SD; n= 5 each. 
*, P<0.05; **, P<0.01; n.s. is not significant. 
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Figure 9. Myeloid development in OP9-DL1 coculture. (A-B) Both wild-type and 
SENP1-/- HSCs cocultured on OP9-DL1 cells were unable to generate B and myeloid 
cells. Sorted FL-HSCs were cultured on OP9-DL1 stromal cells in the presence of 
IL-7 and Flt3L for 7 days. Flow cytometric analysis was performed using B220 and 
CD11b (A) antibodies, and CD11C and CD11b antibodies (B). Data shown are 
representative of three independent experiments.  
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Figure 10. T cell development in OP9-DL1 coculture after 14 days. (A-B) Wild-
type and SENP1-/- FL-HSCs were cultured on OP9-DL1 stromal cells in the presence 
of IL-7 and Flt3L for 14 days. T cells were analyzed by flow cytometry using CD4 
and CD8 antibodies (A). Absolute cell number was counted and presented as means 
± SD; n=5 each (B). **, P<0.01. 
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SENP1 deficiency impairs B cell development 
 
Next, we investigated whether B cell development is also affected by the 
absence of SENP1. We first examined B lymphopoiesis in fetal livers from E14.5 
SENP1-/- embryos and found that SENP1-/- embryos displayed a severe reduction in 
the absolute number of B220+CD19+ B cells compared with wild-type littermate 
controls (Figures 11A and 11B). To further assess the effects of SENP1 deficiency 
on B cell development, we co-cultured FL-HSCs with OP9 stromal cells in the 
presence of Flt3L and IL-7 to promote B cell differentiation in vitro (105). After 7 
days of coculture, flow cytometric analysis revealed an increased frequency of early 
pro-B (B220+CD43+BP-1-CD24+) cells generated from wild-type HSCs. In contrast, 
most B cells generated from SENP1-/- HSCs displayed markers of pre-pro-B 
(B220+CD43+BP-1-CD24-) and early pro-B (B220+CD43+BP-1-CD24+) cells (Figure 
12A).  Furthermore, the absolute numbers of pre-pro-B, early pro-B, late pro-B and 
pre-B cells derived from SENP1-/- HSCs were significantly reduced compared with 
wild-type controls (Figure 12B), suggesting a critical role of SENP1 at the earliest 
stages of B cell development.  
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Figure 11. SENP1 deficiency affects B cell development during embryonic 
development. (A-B) Fetal liver cells were harvested from E14.5 wild-type and 
SENP1-/- embryos. B cells were analyzed by staining with B220 and CD19 
antibodies (A), absolute cell numbers of B220+CD19+ B cells were calculated and 
presented as means ± SD (B); n=5 each. **, P<0.01. 
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Figure 12. SENP1 deficiency results in a severe defect in early B cell 
development. (A) Sorted FL-HSCs from wild-type and SENP1-/- embryos at E14.5 
were cocultured on OP9 stromal cells in the presence of IL-7 and Flt3L. After 7 days 
of coculture, cells were isolated and analyzed by flow cytometry for B cell markers 
B220 and CD43 (top panel), CD24 and BP-1 (Gated CD43+B220+ population, lower 
panel). Data shown are representative of three independent experiments. (B) 
Absolute number of B cells in each developmental stage was calculated based on 
flow cytometry (shown in D) and total cell number, and represented as mean ± SD; 
n= 5 each. *, P<0.05; **, P<0.01; n.s. is not significant. 
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Under OP9 cell coculture conditions, myeloid development was not affected 
in the absence of SENP1 since the absolute number of myeloid cells derived from 
both wild-type and SENP1-/- HSCs remained similar (Figures 12B and 13). After 14 
days of coculture, we also found significant reductions in the frequencies and 
absolute numbers of pro-B and pre-B cells (B220+CD19+) (Figures 14A and 14B), 
and immature B cells (B200+IgM+) derived from SENP1-/- (Figures 14C and 14D). 
These results clearly showed that SENP1 is required for B cell development at the 
early stages. 
 
SENP1 deficiency does not affect myeloid cell development  
 
To demonstrate that the hematopoietic defects caused by SENP1 deficiency 
are restricted to the erythroid (21) and lymphoid lineages, but not the myeloid 
lineage, we co-cultured wild-type and SENP1-/- HSCs with OP9 stromal cells in the 
presence of IL3, IL6, SCF, and Flt3L, and analyzed myeloid cells expressing Gr-1 
and CD11b markers after 7 days of culture. Consistent with our previous report (21), 
no defect in myeloid-lineage development was observed in the absence of SENP1 
since the frequency and absolute number of myeloid cells (Gr-1+CD11b+) generated 
from both wild-type and SENP1-/- HSCs were comparable (Figures 15A and 15B).  
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Figure 13. Myeloid development in OP9 coculture after 7 days. Sorted FL-HSCs 
from wild-type and SENP1-/- embryos at E14.5 were cocultured on OP9 stromal cells 
in the presence of IL-7 and Flt3L. After 7 days of coculture, cells were isolated and 
analyzed by flow cytometry for B cell marker (B220), and myeloid cell marker 
CD11b. Absolute number of myeloid cells was calculated and shown in Figure 7B. 
Data shown are representative of three independent experiments.  
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Figure 14. B cell development in OP9-DL1 coculture after 14 days. (A-D) Wild-
type and SENP1-/- FL-HSCs were cocultured on OP9 stromal cells in the presence of 
IL-7 and Flt3L for 14 days. B cells were analyzed by flow cytometry using B220 and 
CD19 antibodies (A), and B220 and IgM antibodies (B), and their absolute cell 
numbers were calculated and presented as means ± SD (C end D, respectively); n=5 
each. **, P<0.01. Data shown are representative of three independent experiments. 
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Figure 15. SENP1 deficiency does not affect myeloid development. (A-B) Wild-
type and SENP1-/- FL-HSCs were cultured on OP9 stromal cells in the presence of 
IL3 (10ng/ml), IL6 (10ng/ml), SCF (50 ng/ml), and Flt3L (50 ng/ml) for 7 days. 
Myeloid cells were analyzed by flow cytometry using indicated antibodies (A). Data 
shown are representative of three independent experiments. The absolute cell 
numbers of myeloid cells (Gr-1+CD11b+) were calculated based on flow cytometry 
and total cell counts, and presented as means ± SD; n=5 each. n.s. is not significant 
(B).  
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 SENP1 deficiency leads to intrinsic defects in T and B development 
To further confirm that SENP1 deficiency resulted in defects that are intrinsic 
to T and B cell development, we performed FL transplantation experiments using 
RAG-1-/- mice, which lack mature B and T cells (106). FL cells from E14.5 wild-
type and SENP1-/- embryos were transplanted into lethally irradiated RAG-1-/- mice. 
Six weeks after transplantation, the lymphoid compartments of the recipients were 
harvested, counted and analyzed by flow cytometry. Compared with RAG-1-/- mice 
reconstituted with wild-type FL cells (wild-type recipients), the total cell numbers in 
lymphoid organs of RAG-1-/- mice reconstituted with SENP1-/- FL cells (SENP1-/- 
recipients), exhibited a 10- to 20-fold reduction (Figure 16A). Analysis of T cell 
development in the thymi of recipients showed that the frequency of DP T cells in 
the thymi of SENP1-/- recipients was greatly reduced compared with wild-type 
recipients (Figure 16B). Similarly, analysis of B cell development in the bone 
marrow of recipients revealed that the frequencies of CD19+B220+ and 
B220+IgM+IgD- B cells were significantly reduced in SENP1-/- recipients (Figure 
17). Taken together, our data demonstrated that SENP1 deficiency results in intrinsic 
defects in T and B development.  
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Figure 16. SENP1 deficiency impairs T cell development in fetal liver 
transplantation experiments. (A) Cell counts in lymphoid compartments including 
thymus, bone marrow, spleen and lymph node of RAG1-/- mice reconstituted with 
wild-type and SENP1-/- fetal liver cells. Total cell number was calculated and 
represented as mean ± SD; n= 6 each. **, P<0.01. (B) Flow cytometric analysis for T 
cell markers including CD4 and CD8 in the thymi of RAG1-/- mice reconstituted 
with wild-type and SENP1-/- fetal liver cells. Data shown are representative of two 
independent experiments.  
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Figure 17. SENP1 deficiency impairs B cell development in fetal liver 
transplantation experiments. Flow cytometric analysis of B cells in bone marrow 
from RAG1-/- mice reconstituted with wild-type and SENP1-/- fetal liver cells using B 
cell markers B220 and CD19 (upper panel). Gated B220+ cells were further analyzed 
based on IgM and IgD (lower panel). Data shown are representative of two 
independent experiments. 
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SENP1 regulates SUMOylation of STAT5 
 
To check whether SENP1 deficiency may affect transcription of key 
transcription factors crucial for early lymphoid development, we analyzed their 
expression in fetal livers of E14.5 embryos by RT-PCR. Expression levels of PU.1, 
STAT5, GATA3 and E2A from SENP1-/- fetal livers remained unchanged compared 
with those from wild-type littermate controls (Figure 18). To determine whether the 
impaired development of B and T cells in SENP1 deficiency is due to reduced 
expression of IL-7R components, real-time PCR analysis was performed. The 
mRNA levels of IL-7R components including IL-7Rα and γc chains, Jak1 and Jak3 
in fetal livers of E14.4 SENP1-/- embryos were undisturbed, suggesting that the 
expression of genes involved in the IL-7R signaling pathway is intact (Figure 19). 
Indeed, the lymphoid defects in SENP1 deficiency described here are quite similar to 
the one observed in STAT5 deficiency (107-109).  
Given that SENP1 regulated activity of transcription factors (21, 22), we 
therefore hypothesized that SENP1 may control early development of T and B cells 
through altering the SUMOylation status of STAT5. To explore this possibility, we 
first examined SUMOylation of STAT5 in wild-type and SENP1-/- B, T and myeloid 
cells derived from HSC differentiation in vitro after 7 days of coculture by Western 
blot analysis. As shown in Figure 20, the ~95-kDa full-length STAT5 was detected 
in all wild-type and SENP1-/- B, T and myeloid cells, whereas a modified form of 
STAT5 migrating at 135 kDa (~ 40 kDa shift) was observed only in SENP1-/- B and 
T cells. On the other hand, the protein level of another STAT family member, 
 43
STAT3 in SENP1-/- B and T cells was unchanged compared with wild-type B and T 
cells, respectively.  To verify that the ~ 135-kDa band is a SUMOylated form of 
STAT5, lysates of wild-type and SENP1-/- B cells were subjected to denaturing 
immunoprecipitation with anti-STAT5 antibody, followed by immunoblotting with 
anti-SUMO-1 and anti-SUMO-2/3 antibodies. This ~ 135-kDa band displayed in 
SENP1-/- B cells was readily detected with anti-SUMO-2/3, but not by anti-SUMO-1 
or control IgG (Figure 21). These results clearly demonstrate that the modified form 
of STAT5 accumulated in SENP1-/- B and T cells is indeed SUMOylated STAT5. 
Consistent with the accumulation of SUMOylated STAT5, the expression of BCL-2, 
a downstream target of STAT5 was markedly decreased in SENP1-/- B and T cells 
compared with wild-type B and T cells, respectively (Figure 20, third panel). These 
data suggest that deletion of SENP1 results in the accumulation of SUMOylated 
STAT5, which alters its transcriptional activity in early B and T cells.  
To further confirm that SUMOylated STAT5 can be regulated by SENP1, we 
SUMOylated STAT5 by cotransfecting FLAG-tagged STAT5A or STAT5B with 
HA-tagged SUMO-2 constructs in COS-1 cells. In the presence of HA-tagged 
SUMO-2 construct, two major bands migrating at 115 kDa and 135 kDa were 
detected (Figures 22A and 22B). In COS-1 cells, PIAS3 greatly enhanced STAT5 
SUMOylation in a RING-domain-dependent manner (Figure 23). Notably, 
overexpression of SENP1 completely abrogated SUMOylated STAT5, while a 
SENP1 catalytic mutant (C603A mutation) could not deconjugate SUMOylated 
STAT5 (Figure 24). Together, SENP1 plays a critical role in regulating the 
SUMOylation state of STAT5 in vivo. 
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Figure 18. The expression of key transcription factors involved in lymphoid 
differentiation. RNA was isolated from fetal liver cells of SENP1+/+ and SENP1-/- 
embryos at E14.5. RT-PCR was analyzed after normalization with b-actin. The 
results shown are a representative of at least three independent experiments.  
 
 
Figure 19. The expression of IL-7R components. RNA was isolated from fetal 
liver cells of SENP1+/+ and SENP1-/- embryos at E14.5. Quantitative RT-PCR was 
done using TagMan assay kit from ABI. Gene expression was normalized to 18s 
rRNA level. The relative abundance is displayed as an average of triplicates of 
quantitative PCR in each sample, and error bars indicate ± SD. The results shown are 
a representative of at least three independent experiments.  
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Figure 20. Modified STAT5 accumulated in SENP1-/- B and T cells. Sorted FL-
HSCs from wild-type and SENP1-/- embryos at E14.5 were cocultured on OP9 and 
OP9-DL1 cells in the presence of IL-7 and Flt3L to differentiate into B and T cells, 
respectively. After 7 days of coculture, B and T cells were isolated and lysed in 
RIPA buffer. The whole cell lysates were analyzed by immunobloting with anti-
STAT5 (top panel), anti-STAT3 (second panel), anti-BCL-2 (third panel), and anti-
-actin (bottom) antibodies. Wild-type and SENP1-/- myeloid cells derived from 
HSC differentiation on OP9 stromal cells in the presence of IL3 (10ng/ml), IL6 
(10ng/ml), SCF (50 ng/ml), and Flt3L (50 ng/ml) for 7 days were used as controls. 
The results shown are a representative of at least three independent experiments.  
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Figure 21. Endogenous STAT5 is SUMOylated by endogenous SUMO2/3 in 
vivo. B cells isolated from differentiation of wild-type and SENP1-/- FL-HSCs after 7 
days of coculture on OP9 cells were lysed and boiled in denaturing lysis buffer. Cell 
lysates were aliquoted equally for performing immunoprecipitation (IP) by control 
IgG or a mixture of anti-STAT5A and B antibodies. Bound proteins were detected 
by immunoblotting (IB) with anti-SUMO2/3 (top panel), anti-SUMO1 (middle 
panel) or anti-STAT5 (bottom panel) antibodies. Loading samples were 
immunoblotted with anti-STAT5 or anti-actin antibodies. The results shown are a 
representative of at least three independent experiments.  
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Figure 22. Both STAT5A and STAT5B are SUMOylated in an overexpression 
system. COS-1 cells were transfected with FLAG-tagged STAT5A (A) or STAT5B 
(B) and HA-tagged SUMO-2 plasmids. Twenty four hours after transfection, cellular 
protein extracts were immunoprecipitated with anti-FLAG or anti-STAT5B 
antibodies followed by Western blot analysis with anti-HA (top) or anti-FLAG and 
STAT5 B antibodies (bottom). The results shown are a representative of at least 
three independent experiments.  
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Figure 23. SUMOylation of STAT5 is enhanced by PIAS3. COS-1 cells were 
transfected with 1 mg FLAG-STAT5 + 0.5 mg HA-SUMO2 + 0.5 mg Myc-PIAS3wt 
or Myc-PIAS3 mut (mutant ring domain) plasmids. Twenty-four hours after 
transfection, transfected cells were lysed and boiled in denaturing lysis buffer for 5 
min. Protein extracts were immunoprecipitated with anti-FLAG followed by Western 
blot analysis with anti-HA or anti-FLAG antibodies. The input was immunoblotted 
with anti-Myc and anti-HA antibodies. The results shown are a representative of at 
least three independent experiments. 
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Figure 24. SENP1 de-SUMOylates SUMOylated STAT5 in vivo. COS-1 cells 
were transfected with the indicated plasmids. Protein extracts were precipitated with 
anti-STAT5B antibody and analyzed with HA (top) and STAT5 (bottom) antibodies. 
The results shown are a representative of at least three independent experiments. 
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SUMOylation inhibits tyrosine phosphorylation of STAT5  
 
SUMOylation often, but not always, occurs on lysine residues found in the 
consensus motif ΨKXE (where Ψ is any large hydrophobic residue, and X is any 
residue). STAT5 has two SUMO consensus motifs at lysines 384 and 516, and four 
high-scoring non-consensus motifs at lysines 71, 86, 163 and 336 (Figure 25). We 
examined the ability of these sites to be SUMOylated in vivo by introducing single or 
combined mutations (six lysine-to-arginine mutations). Compared with 
SUMOylation of wild-type STAT5, SUMOylation of single mutants or combined 
mutants remained unchanged, suggesting that these lysine residues are not involved 
in SUMOylation of STAT5 (Figure 26).  Previous studies indicate that STAT1 is 
SUMOylated at lysine 703, close to tyrosine 701 (64, 110, 111). Indeed, STAT5A 
contains two lysines at 696 and 700, close to tyrosine 694 (Figure 25). These lysine 
residues of STAT5A/B are well conserved across species including mouse, rat and 
human. SUMOylation of single mutants (K696R and K700R) or double mutant 
(K696/700R) of STAT5A was drastically reduced (Figure 27A). These results 
indicate that lysine residues 696 and 700 are the major sites for SUMOylation of 
STAT5A in vivo. Consistently, the major SUMOylation sites in STAT5B were lysine 
residues 701 and 705 (Figure 27B).  
Since the SUMOylation sites are in close proximity to tyrosine, whose 
phosphorylation is a prerequisite for STAT5 activation, we therefore assessed the 
interplay between STAT5 phosphorylation and SUMOylation. We checked the level 
of STAT5 phosphorylation in SENP1-/- B and T cells derived from HSC 
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differentiation in vitro after 7 days of coculture on OP9 and OP9-DL1 cells in the 
presence of IL-7 and Flt3L, respectively. Western blot analysis showed a marked 
reduction of STAT5 phosphorylation in SENP1-/- B and T cells (Figure 23), 
correlating with an increased SUMOylation (Figure 20). Notably, the 
phosphorylation of STAT5 SUMOylated form could not be detected in SENP1-/- B 
and T cells. These results suggest that in the absence of SENP1, SUMOylation 
inhibits STAT5 phosphorylation and that the accumulation of SUMOylated STAT5 
impairs the activation–inactivation cycle of STAT5 in lymphocytes. 
We further tested the effect of phosphorylation at tyrosine 694 on 
SUMOylation of STAT5. Wild-type STAT5 and constitutively active STAT5 mutant 
N642H were efficiently SUMOylated. In contrast, STAT5 phosphorylation mutant 
Y694A abolished SUMOylation of STAT5 (Figure 29). These results strongly 
suggest that SUMOylation of STAT5 requires a prior phosphorylation or nuclear 
import event since the enzymes involved in SUMOylation are located in the nucleus.  
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Figure 25. Schematic diagram of full-length murine STAT5 protein structure. 
STAT5 contains amino terminal, coiled-coil, DNA binding, linker, SH2, and 
transcriptional activation domains. Arrows indicate approximate locations of two 
putative SUMO consensus motifs at lysines 384 and 516 (Ψ-K-X-E, where ψ 
represents a large hydrophobic amino acid (A, F, I, L, M, V, W) and X represents 
any amino acid), and four other non-consensus motifs at lysines 71, 86, 163 and 336. 
Two lysine residues 696 and 700 located close to Y694 and Y699 of STAT5A and 
STAT5B respectively are underlined.   
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Figure 26. STAT5 is not SUMOylated at lysine residues within the SUMO 
consensus motifs. COS-1 cells were transfected with FLAG-tagged STAT5A and its 
mutants along with HA-SUMO2 plasmids. Protein extracts were immunoprecipitated 
with anti-FLAG and then revealed by Western blot analysis with antibodies to anti-
HA (top) and anti-FLAG (bottom). 5KR: 5 lysine-to-arginine mutations at positions 
71, 86, 336, 384, and 516. 6KR: 6 lysine-to-arginine mutations at positions 71, 86, 
163, 336, 384, and 516. The results shown are a representative of at least three 
independent experiments.  
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Figure 27. mapping STAT5 SUMOylation sites. (A) STAT5A is modified by 
SUMO at lysine residues 696 and 700. COS-1 cells were transfected with FLAG-
tagged STAT5A and its mutants along with HA-SUMO2 plasmids. Protein extracts 
were immunoprecipitated with anti-FLAG and then revealed by Western blot 
analysis with antibodies to anti-HA (top) and anti-FLAG (bottom). The results 
shown are representative of at least three independent experiments. (B) Identification 
of SUMOylation sites in STAT5B. COS-1 cells were transfected with STAT5B and 
its mutants along with HA-SUMO2 plasmids. Immunoprecipitates of STAT5B were 
immunoblotted with anti-HA (top) or anti-STAT5B antibodies (bottom). The results 
shown are a representative of at least two independent experiments.  
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Figure 28. Tyrosine phosphorylation of STAT5 is diminished in SENP1-/- B and 
T cells. Sorted FL-HSCs from wild-type and SENP1-/- embryos at E14.5 were 
cocultured on OP9 and OP9-DL1 cells in the presence of IL-7 and Flt3L to 
differentiate into B and T cells, respectively. After 7 days of coculture, B and T cells 
were isolated and lysed in RIPA buffer. The whole cell lysates (prepared and 
analyzed in Fig. 3A) were further analyzed by immunobloting with anti-P-STAT5 
(top panel) and anti--actin (bottom) antibodies. The results shown are a 
representative of at least three independent experiments.  
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Figure 29. SUMOylation of STAT5 is tyrosine phosphorylation-dependent. 
COS-1 cells were transfected with FLAG-tagged STAT5A (wild-type), STAT5 
phosphorylation mutant Y694A (mutation of tyrosine 694 to alanine) and 
constitutively active STAT5 mutant N642H, and HA-tagged SUMO-2 plasmids. 
Twenty four hours after transfection, Cellular protein extracts were 
immunoprecipitated with anti-FLAG antibody followed by Western blot analysis 
with anti-HA (top) or anti-FLAG antibodies (bottom). The results are a 
representative of at least three independent experiments.  
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SENP1 controls an acetylation/SUMOylation switch in STAT5 
To further understand the effect of SUMOylation on STAT5-mediated 
transcriptional activity, we compared wild-type and SUMOylation-deficient 
STAT5A for their ability to activate transcription in reporter assays. STAT5-
deficient MEF cells stably expressing wild-type STAT5A and its mutants were 
transiently transfected with a luciferase reporter pGL4--Casein. Compared with 
wild-type STAT5A, STAT5A(K700R) exhibited a similar transactivation activity, 
suggesting that SUMOylation of STAT5A at lysine 700 did not play a role in 
transcription regulation (Figure 30). However, STAT5A(K696R) or STAT5A(K696-
700R) showed a markedly decreased in transactivation activity, raising an intriguing 
possibility that lysine 696 may also be subjected to another form of post-translational 
modification.  
Lysine residues can be targeted by multiple modifications, such as 
ubiquitination, SUMOylation, methylation, and acetylation. The carboxy-terminal 
transactivation domain of STAT5 is known to interact with the histone 
acetyltransferase p300/CBP, resulting in enhanced STAT5-dependent transcription 
(112). We hypothesized that lysine 696 is also a target for acetylation. To test this 
possibility, we first checked whether STAT5 can be acetylated by p300. 
Coexpression of p300 in HEK-293 cells significantly enhances STAT5A acetylation 
(Figure 31). Wild-type STAT5A and STAT5A(K700R) mutant, but not 
STAT5A(K696R) and STAT5A(K696-700R) mutants, were acetylated, suggesting 
that lysine 696 is also a major acetylation site (Figure 32). Consistent with our data, a 
recent study indicates that STAT5B acetylation on lysine residues including lysine 
 58
701 (corresponding lysine 696 on STAT5A) is essential for STAT5B dimerization 
since mutation of lysine 701 to arginine impaired STAT5B dimerization and 
transcriptional activity (57).   
Next, we assessed endogenous STAT5 acetylation in wild-type and SENP1-/- 
FL cells. Protein extracts were immunoprecipitated with anti-STAT5 antibody and 
analyzed by immunoblotting with antibody specific for K701-acetylated STAT5B. 
As shown in Figure 33, endogenous STAT5 was acetylated in both wild-type and 
SENP1-/- FL cells treated with IL-7. Notably, STAT5 acetylation in IL7-treated 
SENP1-/- FL cells was significantly decreased compared with that of IL7-treated 
wild-type FL cells, suggesting that SENP1 regulates the acetylation status of STAT5. 
To confirm the role of SENP1 in the regulation of STAT5 acetylation and 
SUMOylation, HEK-293 cells were transfected with FLAG-tagged STAT5A, MYC-
tagged SUMO3, HA-tagged p300 in the presence of RGS-tagged SENP1 or RGS-
tagged SENP1 mutant plasmids. Overexpression of SENP1 enhanced acetylation and 
inhibited SUMOylation of STAT5A (Figure 34). In contrast, overexpression of 
SENP1 mutant decreased acetylation and enhanced SUMOylation of STAT5 (Figure 
34). Taken together, these results demonstrate that SENP1 plays a critical role in 
regulating an acetylation/SUMOylation switch in STAT5.   
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Figure 30. The K696R mutant of STAT5 impairs its transcriptional activity. 
STAT5A/B-deficient MEFs, infected with an empty lentiviral vector (control, CT) or 
lentiviral vectors directing expression of wild-type STAT5, STAT5K696R, 
STAT5K700R or STAT5K696-700R, were transiently transfected with a luciferase 
reporter (pGL4-b-Casein) in triplicates. After 6-hour transfection, the cells were 
cultured in serum-free medium in the presence or absence of GH (200 ng/ml) for 18 
hours. Samples were harvested and evaluated for luciferase and renilla activity. The 
fold induction was calculated as the ratio of luciferase activity in the presence and 
absence of GH. Data shown are representative of three independent experiments. 
Error bars indicate standard deviation. The lower panel shows STAT5 expression 
levels in different clones measured by Western blot analysis with anti-FLAG and 
anti-b-actin (control) antibodies. 
 
 60
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. STAT5 is acetylated by p300. HEK-293 cells (in 6-well plate) were 
transfected with indicated FLAG-tagged STAT5A and HA-tagged p300 plasmids. 
Immunoprecipitation was performed with EZview Red ANTI-FLAG M2 Affinity 
Gel beads and analyzed with anti-acetyl lysine (top panel) and anti-FLAG (second 
panel) antibodies. The results are a representative of at least three independent 
experiments.  
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Figure 32. Lysine 696 is also a target for acetylation. Lysates from HEK-293 cells 
transfected with plasmids expressing FLAG-tagged STAT5A or SUMOylation-
deficient mutants of STAT5A and HA-p300 were immunoprecipitated with EZview 
Red ANTI-FLAG M2 Affinity Gel beads and analyzed with the indicated antibodies. 
The results are representatives of at least three independent experiments.  
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Figure 33. Endogenous STAT5 is acetylated in FL cells treated with IL-7. FL 
cells isolated from three to five E14.5 wild-type and SENP1-/- embryos were treated 
with IL-7 for 10 min and lysed in RIPA buffer. Cellular extracts were 
immunoprecipitated with anti-STAT5 antibody and analyzed with anti-aK701-
STAT5B (top panel) and anti-STAT5 (second panel) antibodies. Loading samples 
were immunoblotted with anti-actin antibody. The results shown are a 
representative of three independent experiments.  
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Figure 34. SENP1 regulates the SUMOylation/acetylation status of STAT5. 
Lysates from HEK-293 Cells (in 6-well plate) transfected with plasmids expressing 
FLAG-tagged STAT5A, MYC-tagged SUMO3, HA-tagged p300 and RGS-tagged 
SENP1w (wild-type) or RGS-tagged SENP1m (mutant) were immunoprecipitated 
with EZview Red ANTI-FLAG M2 Affinity Gel beads and analyzed with anti-acetyl 
lysine (top panel), anti-SUMO2/3 (second panel) and anti-FLAG (third panel) 
antibodies. The input was immunoblotted with anti-RGS, anti-Myc and anti-HA 
antibodies. The results shown are a representative of at least three independent 
experiments. 
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DISCUSSION  
 
SENP1 is essential for early lymphoid development 
SUMOylation has emerged as an important regulatory mechanism for protein 
function (13, 19). SENPs are essential for reversing SUMOylation in many different 
systems, but the physiological functions of SENPs are poorly understood. Recently, 
SENP1 has been shown to play a crucial role in regulating erythropoiesis (20-22). 
However, the physiological function of SENP1 in the development of the immune 
system remains unknown. In the present study, we have discovered that SENP1 is 
essential for early T and B lymphopoiesis.  
The IL-7/IL-7R signaling pathway plays a critical role in regulating T and B 
cell development by controlling several cellular processes, such as cell survival, 
proliferation and VDJ recombination through alteration of chromatin structure.  Loss 
of IL-7R, C or Jak3 gene in mice leads to a severe developmental block of T and 
B cells (113-117), and mutations of these genes results in severe combined 
immunodeficiency in humans (118-121). IL-7 signaling is required for early T cell 
development in the thymus, mainly to protect cells at the DN 2 and DN3 stages from 
apoptotic cell death by regulating the expression of the survival proteins Bcl-2 and 
Mcl-1. Two groups independently crossed IL-7R-deficient mice to mice expressing a 
Bcl2 transgene. As a result, enforced expression of BCL-2 was sufficient to partially 
restore T cell development but was unable to rescue B cell development in IL-7R-
deficient mice (122-124). These studies suggested that the IL-7R signaling not only 
promote pro-B cell survival, but also regulates the expression of other genes required 
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for B cell development. Consistent with this notion, a recent study indicates that IL-
7R signaling is required for stage transition in adult B cell development through up-
regulation of the early B cell transcription factor EBF (125).  
The transcription factor STAT5 is a key molecule downstream of The IL-
7/IL-7R signaling pathway. Earlier analysis of STAT5 knockout mice (STAT5ABΔN/ΔN 
mice), which express N-terminally truncated and partially functional STAT5 
proteins, revealed only a mild defect in T and B cell development (126-128). 
However, a complete inactivation of STAT5A/B in mice (STAT5ABnull/null mice) 
exhibited a profound defect in early T and B cell development (107-109). These 
studies clearly indicate the importance of STAT5 in regulating early T and B cell 
development. Our data indicate that SENP1 deficiency results in severe defects in 
early T and B cell development, similar to that observed in STAT5ABnull/null mice, 
suggesting that STAT5 may be a direct target of SENP1. In agreement with this 
hypothesis, we also found that BCL-2, a key downstream target of STAT5 is 
significantly downregulated in SENP1-/- T and B lymphocytes.  
A possible explanation for the impaired development of both T and B cells 
observed in SENP1-/- embryos could be decreased numbers or function of HSCs. 
However, we have previously reported that HSCs were not affected in SENP1-/- 
embryos (21). Consistent with our previous findings, myeloid development is not 
affected in SENP1 deficiency. We also observed that SENP1 is expressed very high 
in HSCs (Figure 6). This suggests that SENP1 may be required for long-term self-
renewal capacity of HSCs. Future studies are needed to address this important issue. 
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STAT5 is regulated by the SUMOylation pathway 
PIAS proteins were initially identified as negative regulators of STAT 
signaling that inhibit the activity of STAT-transcription factors (58, 59). The exact 
molecular mechanisms by which the PIAS proteins inhibit STAT activity remain 
unclear, although several models have been proposed. For example, PIAS proteins 
bind only to activated STAT dimmers in the nucleus and inhibit their DNA-binding 
activity. Other possible explanation for the role of PIAS proteins in the regulation of 
STAT activity is that PIAS protein can recruit other co-regulators, including histone 
deacetylases (HDACs), to repress transcription. A recent study reported that PIAS1 
binding to the Foxp3 promoter leads to recruitment of DNA methyltransferases and 
heterochromatin protein 1 for epigenetic modifications (61). Pias1 deficiency results 
in promoter demethylation, reduced histone H3 methylation at Lys9, and enhanced 
promoter accessibility. Interestingly, deletion of PIAS1 leads to the enhanced 
binding of STAT5, a key transcription factor involved in Foxp3 induction to the 
Foxp3 promoter. As a result, PIAS1-/- mice exhibit the increased frequency of 
Foxp3+ CD4+CD8+ thymocytes (61). In deed, SUMOylation of many transcription 
factors results in alterations of their localization or interaction with binding partners. 
In most cases, SUMOylated proteins suppress transcription, possibly due to their 
interaction with co-repressors. Thus, the mechanism that SUMOylation regulates 
transcription is quite similar to that a PIAS protein suppresses the transcriptional 
activity of transcription factors. It is likely that PIAS proteins regulate the 
transcriptional activity of transcription factors through the SUMOylation pathway. 
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PIAS proteins have SUMO-specific E3 ligase activity, and have been shown 
to promote the SUMOylation of numerous transcription factors, such as p53, LEF1 
and c-Jun (129-131). These studies raised the possibility that STAT activity might be 
regulated by the SUMOylation pathway. It was previously shown that STAT1 are 
SUMOylated on Lysine 703 in an overexpression system (63, 64, 111). However, the 
in vivo function of SUMOylation in the regulation of STAT1 activity remains 
unclear. In addition, it is not known whether other STATs can be modified by 
SUMO. In this study, we found that SUMOylation negatively regulates STAT5 
activity. The accumulation of SUMOylated STAT5 results in suppression of STAT5 
activity and subsequent signaling events in SENP1-/- T and B cells. Although we also 
found that STAT5 SUMOylation is greatly enhanced by PIAS3 in an overexpression 
system, further studies will be required to define whether this SUMO-specific E3 
ligase is involved in regulation of STAT5 activity in vivo.    
 
SENP1 regulate STAT5 SUMOylation  
Protein function is tightly regulated by reversible posttranslational 
modifications to create an on and off state that is crucial for many biological 
processes. Many proteins are dynamically modified at multiple sites by different 
modifications (26). The histone code hypothesis has been proposed that distinct 
histone modifications, on one or more tails, act alone, sequentially or in combination 
to form a 'histone code' that is then read by effector proteins to bring about distinct 
downstream events (132). On the histone H3 tail, lysines 9 and 27 are well-known 
methylation sites, and methylation of these sites is ‘read’ by heterochromatin protein 
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1 (HP1) and Polycomb (Pc), leading to heterochromatin-mediated gene silencing 
(Lys 9) and epigenetic repression (Lys 27), respectively (133, 134). It is noteworthy 
that lysines 9 and 27 are located the “RK9S” or “RK27S” motif. According to the 
“methyl/phos switch” model, serine phosphorylation of the “RKS” motif that 
engages an HP1 or Pc module could lead to consecutive loss of binding (44). 
The interplay between phosphorylation and SUMOylation of neighboring 
sites has been shown to play an important role in regulating the transcriptional 
activity of many transcription factors. For example, heat-shock factors (HSFs), 
GATA-1 and myocyte enhancer factor 2 (MEF2), containing a SUMO consensus site 
and an adjacent proline-directed phosphorylation site (ΨKxExxSP), are regulated by 
phosphorylation-dependent SUMOylation (27, 28, 135). The motif ΨKxExxSP 
couples sequential phosphorylation and SUMOylation and has been referred to as a 
“Phospho-SUMOyl switch” (26). It has been shown that STAT1 SUMOylation at 
lysine 703 inhibits its phosphorylation at tyrosine 701 (136). In addition, STAT1 
SUMOylation at lysine 703 and STAT1 phosphorylation at tyrosine 701 are mutually 
exclusive (137). We have identified two SUMOylation sites of STAT5 at lysines 696 
and 700, located in close proximity to tyrosine 694, whose phosphorylation is a 
prerequisite for STAT5 activation, suggesting a possible interplay between 
SUMOylation and phosphorylation in regulating STAT5 activity. Indeed, 
SUMOylation of STAT5 is phosphorylation-dependent, since STAT5 
phosphorylation mutant Y694A abolished SUMOylation of STAT5 (data not 
shown). We also found that SENP1 deficiency causes increased STAT5 
SUMOylation, correlating with diminished STAT5 phosphorylation and activity in 
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lymphocytes (Figures 20 and 28), suggesting that SUMOylation of STAT5 inhibits 
its phosphorylation and subsequent signaling events. Interestingly, SUMOylation of 
STAT5 observed in the absence of SENP1 appears to be lymphocyte specific, since 
no SUMOylated STAT5 could be detected in SENP1-/- myeloid cells (Figure 20). 
Further investigations are required to resolve this issue. 
 
The acetylation/SUMOylation switch in STAT5 is regulated by SENP1 
Since lysine can be a target of different posttranslational modifications, 
SUMOylation can block alternative lysine-targeted modifications, such as 
ubiquitination, methylation or acetylation. It was previously reported that IκBα is 
SUMOylated on K21, which is also targeted by ubiquitination (29). Transcriptional 
activity of several transcription factors, such as SP3, HIC1 and MEF2A can be 
regulated by interplay between SUMOylation and acetylation on the same lysine 
residue (30, 31, 138). An acetylation-SUMOylation switch on MEF2 is further 
regulated by its phosphorylation (31). In addition to tyrosine phosphorylation, 
acetylation of different STATs has been shown to play a critical role in regulating 
their activity (52, 53, 55, 56). For example, STAT3 acetylation at lysine 685 is 
essential for its dimerization and transcriptional activity (55). Here, our data clearly 
show that STAT5A is acetylated at lysine 696, which is also a target for 
SUMOylation. Acetylation of STAT5 at lysine 696 is essential for STAT5 
activation, since mutation of this lysine diminished the transcriptional activity of 
STAT5 (Figure 30). Consistent with our finding, a recent study has reported that 
STAT5B acetylation on lysine 701 (corresponding lysine 696 on STAT5A) is 
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essential for STAT5B dimerization and transcription (57). Notably, our data provide 
direct evidence that SENP1 regulates an acetylation/SUMOylation switch in STAT5.  
 
Proposed model 
Based on the findings reported here, we propose a model for the role of 
SENP1 in the regulation of an acetylation-SUMOylation switch in STAT5 (Figure 
35). In unstimulated cells, STAT5 exists in the cytoplasm as a monomer. Upon 
activation, tyrosine-phosphorylated and acetylated STAT5 dimerizes, translocates to 
the nucleus, and activates transcription. We currently do not know which signal 
induces the acetylation/SUMOylation switch in STAT5. Since we did not observe 
the phosphorylation of STAT5 SUMOylated form in SENP1-/- B and T cells (Figure 
20), it seems likely that dephosphorylation of STAT5 promotes a switch from 
acetylation (active state) to SUMOylation (inactive state). It is also possible that 
SUMOylation of STAT5 facilitates its dephosphorylation. SENP1 protein, which is 
predominantly present in the nucleus (16), is required for de-conjugating 
SUMOylated STAT5 before it returns to the cytoplasm to complete an activation-
inactivation cycle. In the absence of SENP1, STAT5 is accumulated in the 
SUMOylation state, leading to inhibition of STAT5 phosphorylation and acetylation, 
and subsequent signaling events. Thus, our findings establish a specific role of 
SENP1 in regulating lymphoid development via an acetylation/SUMOylation switch 
in STAT5.  
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Figure 35. A model for the role of SENP1 in the regulation of acetylation-
SUMOylation switch in STAT5. SUMOylation switches STAT5 from an active 
state to an inactive state. SENP1 is required to remove SUMO from conjugated 
STAT5, allowing it to re-enter the activation-inactivation cycle. * is lysine 696 in 
STAT5A or lysine 701 in STAT5B; A is acetylation; P is phosphorylation. 
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In conclusion, our study has provided evidence that SENP1 controls early T 
and B lymphopoiesis through the regulation of an acetylation/SUMOylation switch 
in STAT5. SENP1 deficiency results in severe defects in early T and B cell 
development. Our data clearly demonstrate that SENP1 regulates STAT5 activity via 
an acetylation/SUMOylation switch in STAT5. SENP1 deficiency causes the 
accumulation of SUMOylated STAT5, thus preventing STAT5 to re-enter another 
activation-inactivation cycle, which contributes to defective early T and B cell 
development. The acetylation/SUMOylation switch may acts as an important 
mechanism involving in the regulation of transcription in the immune system to turn 
the signaling ON and OFF in response to cytokines or pathogens.  
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 MATERIALS AND METHODS 
Mice 
The generation and screening of SENP1-/- fetuses has been described 
previously (21). SENP1+/- mice were intercrossed, and E14.5 fetuses (date of plug = 
E0.5) were obtained for FL isolation.  RAG1-/- mice were obtained from The Jackson 
Laboratory. All animal protocols used in this study were approved by the 
Institutional Animal Care and Use Committee at The University Texas M. D. 
Anderson Cancer Center. 
 
Plasmids  
The full-length cDNA of murine STAT5A was amplified from the retroviral 
vector pMIG-STAT5 (a gift of Drs. Yong-Jun Liu & Stephanie S. Watowich, UT-
MD Anderson cancer center), and then subcloned into p3xFLAG-CMV™-7.1 
Expression Vector (Sigma, St Louis, MO) using standard techniques. Rat STAT5b 
pcDNA3.1- was a kind gift from Dr. L.-Y. Yu-Lee (Baylor College of Medicine). 
Myc-tagged wild-type mouse PIAS3 and Myc-tagged mouse PIAS3 RING domain 
mutant were generously provided by Dr. Fang Liu (Rutgers University). pGL4 
mouse -Casein reporter plasmid was kindly given by Dr. Koichi Ikuta (Kyoto 
University). pGL4.74 [hRluc/TK] vector was from Promega. HA-p300 plasmid was 
described earlier (139). HA-SUMO2, Flag-SENP1, and Flag-SENP1 catalytic mutant 
plasmids were generated in our laboratory. STAT5 mutants were generated by using 
a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). 
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 Antibodies and Cytokines 
Anti–Flag (M2, F3165) was from Sigma. Anti–HA (influenza hemagglutinin) 
(16B12, MMS-101P) was from Covance. Anti-RGS (34610) was from QIAGEN. 
Anti-Myc (9E10) was from Santa Cruz Biotechnology. Monoclonal anti-SUMO-1 
antibody (anti-GMP-1) was from Zymed. Anti-SUMO-2/3 was purchased from 
Abgent. Anti-STAT5 (C-17) and anti-STAT3 (C-20) antibodies were from Santa 
Cruz Biotechnology. Antibodies for STAT5A and STAT5B were from R&D 
Systems. Anti-phospho-STAT5 was from cell Signaling. Anti-Bcl-2 antibody 
(610538) was from BD Biosciences. Anti-acetylated-lysine antibody (9441s) was 
from Cell Signaling. Anti-aK701-STAT5b was from Dr. Y. Eugene Chin (Brown 
University) and described previously (57). Anti--Actin was from Sigma.  
All cytokines, including murine IL-7, murine Ilt3 ligand, murine IL-3, murine 
IL-6 and murine SCF, were purchased from Peprotech (Rocky Hill, NJ).  
 
Monoclonal antibodies and flow cytometry 
All monoclonal antibodies used in this study were from BD Pharmingen: 
anti-c-Kit (2B8; APC), anti-Sca-1 (E13-161.7; PE and D7; FITC), anti-TER-119 
(TER-119; FITC, APC, PE), anti-CD11b (M1/70; FITC), anti-Gr-1 (RB6-8C5; 
PerCP-Cy5.5), anti-CD19 (1D3; PerCP-Cy5.5), anti-CD4 (RM4-5; PerCP-Cy5.5 and 
GK1.5; FITC), anti-CD8a (53-6.7; PerCP-Cy5.5, APC), anti-CD44 (Pgp-1; FITC, 
IM7; APC), anti-CD25 (7D4; FITC, PE), anti-mouse early B lineage (AA4.1; FITC), 
anti-CD24 (M1/69; FITC), anti-BP1 (6C3; PE, biotin), anti-CD43 (S7; FITC, biotin), 
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anti-B220 (RA3-6B2; APC, PE), anti-IgM (II/41; APC). For detection biotinated 
antibodies, streptavidin-APC and PerCP-Cy5.5 (BD Pharmingen) were used.  
Single-cell suspensions were first incubated on ice with rat anti-mouse 
CD16/CD32 (BD PharMingen) to block nonspecific binding to Fc receptors. 
Subsequently, cells were incubated with indicated antibodies and analyzed using a 
LSR II flow cytometer or FACS-Calibur machine and the FlowJo analyzing software 
(Treestar).  
 
Purification of FL-HSCs  
E14.5 fetal liver cells were harvested and treated with red blood cell lysis 
buffer (Sigma). Then, cells were stained with anti-c-Kit-APC and anti-Sca-1-PE 
antibodies, and a mixture of antibodies to lineage markers: Gr-1, CD11b. TER-119, 
CD19, CD4 and CD8. FL-HSCs (lin- c-KithighSca-1high) were sorted using FACSAria 
cell sorter (BD Biosciences).   
 
B and T cell differentiation in vitro 
OP9 and OP9-DL1 stromal cell lines (generous gifts from Dr. Juan Carlos 
Zúñiga-Pflücker, University of Toronto, Toronto, Canada) were co-cultured as 
previously described (104). Briefly, stromal cells were maintained in alpha-MEM 
(Gibco BRL) containing 20% FBS (Gibco BRL) and penicillin–streptomycin 
(Sigma-Aldrich). Wild-type and SENP1-/- FL-HSCs (1000-3000 cells/well in 24-well 
plates) were placed on OP9 and OP9-DL1 monolayers, for B and T lineage 
differentiation, respectively. Co-culture media contained: alpha-MEM, 10% FBS, 10 
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mM HEPES (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL), 2 mM GlutaMax, 
penicillin–streptomycin, 50 mM 2-mercaptoethanol, 5 ng/ml IL-7 and 5 ng/ml Flt3L. 
After 4 days of culture, the cells were passed onto newly prepared OP9 and OP9-
DL1 cells. For myeloid differentiation, wild-type and SENP1-/- FL-HSCs were 
placed on OP9 monolayers in the presence of IL3 (10ng/ml), IL6 (10ng/ml), SCF (50 
ng/ml) and Flt3L (50 ng/ml). 
  
Transplantation experiments  
Two x 106 fetal liver cells isolated from E14.5 wild-type and SENP1-/- 
embryos were injected intravenously into lethally (950 rad) irradiated RAG-1-
deficient mice. Mice were sacrificed 5-6 weeks after transplantation. The lymphoid 
compartments of the recipients were analyzed by flow cytometry. The experiments 
shown in this study represent results from two independent experiments.  
 
RNA Extraction and real time PCR assay  
Total RNA was extracted using the RNeasy Mini Kit from QIAGEN and 
converted into cDNA using Advantage RT-for-PCR Kit (Clontech) according the 
protocols described in the handbooks. Quantitative RT-PCR were performed using 
TagMan gene expression assay from (Applied Biosystems) and analyzed on the 
GeneAmp 7700 sequence detection system (Applied Biosystems). Gene expression 
was normalized to 18s rRNA level. The relative abundance is displayed as an 
average of triplicates of quantitative PCR in each sample, and error bars indicate ± 
SD. All primers were purchased from Applied Biosystems: mouse SENP1 
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(Mm00522968_m1), mouse interleukin 7 receptor (Mm00434295_m1), mouse Janus 
kinase 3 (Mm00439962_m1), mouse Janus kinase 1(Mm00600614_m1), mouse 
interleukin 2 receptor gamma chain (Mm00442885_m1), eukaryotic18s rRNA 
(4319413E). 
RT-PCR was performed using gene specific primers: PU1, E2A and GATA3 
(140). The primers for STAT5 and -Actin were described previously (21).  
 
Luciferase assays  
STAT5 and its mutants were constructed in pCDH-T2AcGFP-MSCV 
(System Biosciences). The lentiviruses were generated according to the 
manufacturer's protocol (System Biosciences). STAT5A/B-deficient MEFs (a kind 
gift from Dr. James N. Ihle at the St. Judes Childrens Research Hospital) infected 
with an empty lentiviral vector (control) or lentiviral vectors directing expression of 
wild-type STAT5A and its mutants including STAT5K696R, STAT5K700R or 
STAT5K696-700R, were transiently transfected with luciferase reporter (pGL4--
Casein) and pGL4.74 [hRluc/TK] plasmids in triplicate using FuGENE HD (Roche). 
After 6-hour transfection, the cells were cultured in serum-free medium in the 
presence or absence of GH (200 ng/ml) for 18 hours. Samples were harvested and 
evaluated for luciferase and renilla activity. The fold induction was calculated as the 
ratio of luciferase activity in the presence and absence of GH. Data are representative 
of three independent experiments. Error bars indicate standard deviation.  
  
Western blot analysis 
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B, T and myeloid cells derived from HSC differentiation on day 7 of 
coculture with OP9 cells and OP9-DL1 cells were harvested and filtered through a 
70-µm filter to exclude pieces of disrupted monolayer. After washing twice with ice-
cold PBS, the cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
Triton X-100, 1% Sodium deoxycholate , 0.1 % SDS, [pH 7.5]) supplemented with 
complete protease inhibitor cocktail and 20 mM N-Ethylmaleimide (NEM, 
Sigma).Whole-cell protein extracts were prepared and quantified by the Bradford 
method (Bio-Rad, Hercules, CA). Equal amounts of protein (20 g/lane) was 
electrophoretically separated on SDS-PAGE and transferred to a PVDF membrane. 
The membranes were blotted with indicated antibodies. An anti-rabbit or anti-mouse 
antibody conjugated to horseradish peroxidase was used as secondary antibodies, and 
the signal was detected using a chemiluminescence kit (PerkinElmer, Wellesley, 
MA).  
 
Immunoprecipitation  
For in vivo SUMOylation assay, COS-1 cells were transfected with indicated 
plasmids. At 24 hr after transfection, cells were lysed with immunoprecipitation 
buffer (10 mM phosphate buffer, 10 mM Tris, 150 mM NaCl, 1% Triton X-100, and 
20 mM NEM [pH 7.5]) containing a protease inhibitor cocktail, and 
immunoprecipitated with the indicated  antibodies or EZview Red Affinity Gel 
matrix (Sigma, St. Louis, MO). For in vivo acetylation assay, HEK-293 cells were 
transfected with indicated plasmids. After 48-hour transfection, cells were lysed in 
RIPA buffer containing a protease inhibitor cocktail, 10 mM nicotinamide and 
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500nM trichostatin A, and immunoprecipitated with the indicated antibodies. For 
denaturing immunoprecipitation, the cells were lysed in 0.2 ml denaturing IP buffer 
(1% SDS, 50 mM Tris, 10 mM DTT, [pH 7.5]) and boiled for 5 minutes. 
Subsequently, denatured proteins were diluted in immunoprecipitation buffer and 
immunoprecipitated with the indicated antibodies. Immunoprecipitated proteins were 
resolved by SDS/PAGE and analyzed by immunoblotting.   
 
Statistical analysis. 
 Data are presented as mean ± one standard deviation (SD); p values were 
calculated using an unpaired two-tailed Student’s t test in the Microsoft Excel 
software. P > 0.05 was considered to be not significant; *, P < 0.05 and **, P < 0.01 
means significant and very significant, respectively.  
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